Description of the participants for model developing by gender
| Variable | Male | Female | ||
|---|---|---|---|---|
| Control | CHD | Control | CHD | |
| (n=400) | (n=664) | (n=227) | (n=385) | |
| Age (year) | 45.5±12.1 | 63.3±11.2 | 43.3±10.4 | 62.5±9.0 |
| UA (µmol/L) | 404.9±86.1 | 387.8±96.4 | 282.6±61.3 | 323.9±84.4 |
| TC (mmol/L) | 4.9±0.9 | 4.7±1.0 | 4.5±0.8 | 4.9±1.1 |
| TG (mmol/L) | 1.2 (0.9, 1.7) | 1.6 (1.2, 2.4) | 1.9 (1.3, 3.1) | 1.5 (1.2, 2.4) |
| HDL-C (mmol/L) | 1.3±0.4 | 1.1±0.3 | 1.6±0.3 | 1.2±0.3 |
| LDL-C (mmol/L) | 3.0±0.8 | 2.8±1.0 | 2.7±0.7 | 2.7±0.9 |
| apoA (g/L) | 1.5±0.3 | 1.2±0.3 | 1.6±0.2 | 1.3±0.2 |
| apoB (g/L) | 1.1±0.2 | 0.9±0.3 | 0.9±0.2 | 0.9±0.3 |
| Lp(a) (mg/L) | 188.0 (110.0, 361.0) | 199.0 (96.0, 376.0) | 180.5 (108.5, 353.5) | 146.5 (61.0, 283.5) |
| HCY (µmol/L) | 7.1 (4.3, 9.7) | 17.0 (12.4, 18.9) | 11.9 (8.6, 14.9) | 18.3 (14.9, 21.4) |
| TBil (µmol/L) | 11.5 (8.9, 14.5) | 9.9 (7.5, 13.0) | 13.6(10.8, 17.6) | 12.4(9.2, 16.05) |
| Dbil (µmol/L) | 2.9 (2.3, 3.7) | 3.5 (2.5, 4.5) | 3.5 (2.8, 4.5) | 3.3 (2.4, 4.7) |
| IBil (µmol/L) | 8.6 (6.7, 10.8) | 6.1 (4.5, 9.1) | 10.0 (7.9, 13.2) | 8.9 (5.9, 12.1) |
| GGT (IU/L) | 15.0 (11.0, 22.0) | 30.5 (20.0, 49.0) | 36.0 (21.0, 63.5) | 38.0 (26.0, 60.5) |
Normally distributed data were presented as means±SD, skewed data were presented as the median (IQR).
apoA, apolipoprotein A; apoB, apolipoprotein B; CHD, coronary heart disease; DBil, direct bilirubin; GGT, γ-glutamyl transpeptidase; HCY, homocysteine; HDL-C, high-density lipoprotein cholesterol; IBil, indirect bilirubin; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); TBil, total bilirubin; TC, total cholesterol; TG, triglyceride; UA, uric acid.